C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.

Abstract

Background and aimLenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients likely to benefit from lenvatinib treatment.MethodsWe retrospectively analyzed 53 patients who were treated with lenvatinib for unresectable HCC. They were divided to two groups; low C-reactive protein (CRP) group with pretreatment serum CRP level ResultsThe high CRP group showed a significantly poorer OS than the low CRP group (0.0% vs 71.5%/ 1year, p ConclusionsCRP level was associated with OS in HCC patients treated with lenvatinib. CRP could be a useful marker to identify patients most likely to benefit from lenvatinib treatment.